Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Prothena Corporation plcNASDAQ: PRTA

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) turns positive

Q1 FY2026 EPS (Basic) was $0.61, compared with -$1.12 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.81.

Context

  • EPS (Basic) grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 4 analysts of -$0.02 (+99.5%) for the fiscal year ending Dec 2026, a step up from the -99.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0.61+252.5% QoQ
Last fiscal yearDec 2025
-$4.53-99.6% YoY
LTMMar 2026
-$2.81-36.4% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+154.5%+83.3%-71.1 pp
1 year-99.6%+99.5%+199.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(4.53) USD
Year-over-year change
-99.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -36.4% is the 8th highest of 10, against a peer median of -1.4%.
PRTA Competitors
EPS (Basic) for PRTA and competitors
Company Period LTM YoY 3-year CAGR
BIIBBiogen Inc.LTM Jun 2026$5.68 USD-45.9%-25.0%
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$0.26 USD+64.6%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025-$0.46 USD+15.7%—
ACIUAC Immune S.A.LTM Mar 2026-CHF 0.66 CHF-32.0%—
ANNXAnnexon, Inc.LTM Mar 2026-$1.22 USD-3.4%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$1.33 USD+17.4%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$1.87 USD+3.6%—
PRTAProthena Corporation plcLTM Mar 2026-$2.81 USD-36.4%—
DNLIDenali Therapeutics Inc.LTM Jun 2026-$2.84 USD-1.4%—
PMNProMIS Neurosciences, Inc.LTM Jun 2026-$16.89 USD-243.3%—
Peer median (excluding PRTA) —-1.4%-25.0%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.